Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF

R&D Systems | Catalog # 4586-KS

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems Sf 9 (baculovirus)-derived Recombinant Human Active MAP3K8/Tpl2/COT Protein (4586-KS)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

Sf 9 (baculovirus)

Accession Number

NM_005204

Applications

Bioactivity
View all MAP3K8/Tpl2/COT Proteins and Enzymes »

Product Specifications

Source

Spodoptera frugiperda, Sf 9 (baculovirus)-derived human MAP3K8/Tpl2/COT protein
aa 30-397

Purity

>75%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

N-terminal Sequence Analysis

Using an N-terminal GST tag

SDS-PAGE

70 kDa

Activity

The specific activity of COT is typically 860-1164 nmol/min/mg using MEK1 and ERK1 substrates and a myelin basic protein (MBP) substrate.

Scientific Data Images for Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF

Recombinant Human Active MAP3K8/Tpl2/COT Protein SDS-PAGE.

Recombinant Human Active MAP3K8/Tpl2/COT Protein SDS-PAGE

The approximate molecular weight is 70 kDa and the purity is > 75%.

Formulation, Preparation, and Storage

4586-KS
Formulation Supplied in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM Glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, and 25% Glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage This product is stable at ≤ ‑70 °C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.

Background: MAP3K8/Tpl2/COT

COT is an oncogene that can activate both the MAP kinase and JNK kinase pathways. COT activates I kappa B kinases and induces the nuclear production of NF-kappa B. The C-terminal catalytic domain of KSR2 associates with COT and KSR2 can negatively regulate the kinase activity of COT in vitro. Co-transfection of KSR2 with COT in cells lead to reduced COT-mediated ERK activation and COT induced IL-8 production in a dose-dependent manner (1). COT is one of the MAP kinase kinase (MAPKK) kinases that regulates the ERK1/ERK2 pathway in response to IL-1. Blockage of expression of COT results in failure of IL-1 to induce an increase in IL 8 and MIP-1 beta mRNA levels (2).

References

  1. Channavajhala, P.L. et al. (2003) J. Biol. Chem. 278:47089.
  2. Rodriguez, C. et al. (2006) Cell Signal. 18:1376.

Long Name

Mitogen-activated Protein Kinase Kinase Kinase 8

Alternate Names

COT, EST, ESTF, MAP3K8, Tpl-2

Entrez Gene IDs

1326 (Human); 26410 (Mouse); 116596 (Rat)

Gene Symbol

MAP3K8

UniProt

NM_005204 (Human)

Additional MAP3K8/Tpl2/COT Products

Product Documents for Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF

For research use only

Customer Reviews for Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF and earn rewards!

Have you used Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human Active MAP3K8/Tpl2/COT Protein, CF (4586-KS):

Materials
  • Active Kinase - Active COT (0.1 μg/μL) diluted with Kinase Dilution Buffer III and assayed as outlined in Sample Activity Plot. Note: These are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active COT for optimal results.
  • Kinase Assay Buffer I - 25 mM MOPS, pH 7.2, 12.5 mM beta -glycerolphosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA. Add 0.25 mM DTT to the Kinase Assay Buffer prior to use.
  • Kinase Dilution Buffer III - Kinase Assay Buffer I diluted at a 1:4 ratio (5X dilution) with a 50 ng/μL BSA solution.
  • 10 mM ATP Stock Solution - Prepare ATP Stock Solution by dissolving 55 mg of ATP in 10 mL of Kinase Assay Buffer I. Store 200 μL aliquots at ≤ -20 °C.
  • [33P]-ATP Assay Cocktail - Prepare 250 μM [33P]-ATP Assay Cocktail in a designated radioactive work area by combining 150 μL of 10 mM ATP Stock Solution, 100 μL of [33P]-ATP (1 mCi/100 μL), and 5.75 mL of Kinase Assay Buffer I. Store 1 mL aliquots at ≤ -20 °C.
  • Substrate - Inactive MEK1 and ERK1 were activated in a coupled reaction. Myelin Basic Protein (MBP) diluted in distilled or deionized water to a final concentration of 1 mg/mL was subsequently used as a substrate for the activated ERK1.
  1. Thaw the Active COT, Kinase Assay Buffer I, and inactive MEK1 and ERK1 on ice. In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μL:
    a. Diluted Active COT: 10 μL
    b. Inactive MEK1 (0.2 μg/μL): 2 μL
    c. Inactive ERK1 (0.2 μg/μL): 3 μL
    d. Kinase Dilution Buffer: 5 μL
  2. Start the reaction with the addition of 5 μL ATP (250 μM) and incubate in a water bath at 30 °C for 25 minutes.
  3. After the 25 minute incubation, remove 5 μL and add to the following reaction components bringing the initial reaction volume up to 20 μL:
    a. Reaction Mixture: 5 μL
    b. Distilled water (on ice): 10 μL
    c. MBP Substrate (1 mg/mL; on ice): 5 μL
  4. Set up the blank control as outlined in Step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled water.
  5. Initiate the reaction with the addition of 5 μL [33P]-ATP Assay Cocktail, bringing the final volume up to 25 μL and incubate the mixture in a water bath at 30 °C for 15 minutes.
  6. After the 15 minute incubation, terminate the reaction by spotting 20 μL of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
  7. Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (add 10 mL of phosphoric acid to 990 mL of distilled or deionized water) with constant gentle stirring. It is recommended that the strips be washed a total of three times for approximately 10 minutes each.
  8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
  9. Determine the corrected cpm by subtracting the blank control value (see step 4) for each sample and calculate the kinase specific activity as outlined below.


    Calculation of [33P]-ATP Specific Activity (SA) (cpm/pmol)
    Specific Activity (SA) = cpm for 5 μL [33P]-ATP/pmole of ATP (in 5 μL of a 250 μM ATP stock solution; i.e. 1250 pmol)

    Calculation of Kinase Specific Activity (SA) (pmol/minutes/μg or nmol/minutes/mg)
    Corrected cpm from reaction / [(SA of 33P-ATP in cpm/pmol) x (Reaction time in minutes) x (Enzyme amount in μg or mg)] x [(Reaction volume) / (Spot Volume)]

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes